Earnings
NLTX
10.15
-1.07%
-0.11
Currencies: USD
Items
Cash and Cash Equivalents
Short-term Investments
Short-term Securities
Accounts Receivable
Notes Receivable
Interest Receivable
Other Receivables
Prepayments
Inventories
Holding Assets for Sale
Unamortized Expenditures
Other Current Assets
Total Current Assets
Fixed Assets Net
Long-term Receivables
Long-term Investments
Deferred Tax Asset
Goodwill
Intangible Assets
Long-term Deferred Expenses
Other Non-current Assets
Total Non-current Assets
Total Assets
Short/Current Long Term Debt
Accounts Payable
Notes Payable
Taxes and Dues Payable
Salary Payable
Financing Expenses Payable
Other Payable
Advance Receipt
Accrued Expenses
Deferred Income
Holding Liabilities For Sale
Financial Derivative Liabilities
Other Current Liabilities
Total Current Liabilities
Long-term Debt
Long-term Payables
Long-term Deferred Income
Long-term Deferred Tax Liabilities
Other Non-current Liabilities
Total Non-current Liabilities
Total Liabilities
Common Stocks
Additional Paid-in Capital
Retained Earnings
Treasury Shares
Other Equity Instruments
Minority Interest
Equities Attributable to Parent Company
Total Equities
Total Liabilities and Equities
FY 2020-12-31
192.56M
--
--
900.00K
--
--
0.00
--
--
--
--
1.07M
194.52M
13.72M
--
--
--
--
347.00K
--
1.93M
16.00M
210.52M
--
1.32M
0.00
--
--
--
--
--
6.52M
--
--
--
--
7.89M
108.00K
--
--
--
11.31M
11.41M
19.30M
0.00
524.02M
-332.81M
--
--
--
191.22M
191.22M
210.52M
FY 2019-12-31
143.09M
--
--
503.00K
--
--
0.00
--
--
--
--
--
143.60M
2.83M
--
--
--
--
567.00K
--
30.00K
3.43M
147.02M
--
1.60M
0.00
--
--
--
--
--
3.08M
--
--
--
339.00K
4.74M
146.00K
--
--
--
447.00K
593.00K
5.34M
0.00
441.22M
-299.53M
--
--
--
141.69M
141.69M
147.02M
FY 2018-12-31
76.93M
0.00
--
237.00K
--
--
0.00
--
--
--
--
--
77.17M
400.00K
--
--
--
--
--
--
53.00K
453.00K
77.62M
--
702.00K
0.00
--
--
--
--
--
3.92M
--
--
--
249.00K
4.63M
6000.00
--
--
--
313.00K
319.00K
4.95M
0.00
302.76M
-230.09M
--
--
--
72.67M
72.67M
77.62M
FY 2017-12-31
52.03M
56.05M
--
740.00K
--
--
0.00
--
--
--
--
--
108.83M
905.00K
--
0.00
--
--
--
--
599.00K
1.50M
110.33M
--
6.02M
0.00
--
--
--
--
--
4.94M
--
--
--
720.00K
10.96M
33.00K
--
--
--
453.00K
486.00K
11.44M
0.00
297.46M
-198.50M
--
--
--
98.89M
98.89M
110.33M
FY 2016-12-31
32.30M
70.76M
--
426.00K
--
--
0.00
--
--
--
--
--
103.48M
849.00K
--
50.05M
--
--
--
--
--
50.90M
154.38M
--
6.86M
0.00
--
--
--
--
--
2.66M
--
--
--
66.00K
9.52M
47.00K
--
--
--
150.00K
197.00K
9.72M
0.00
293.11M
-148.28M
--
--
--
144.66M
144.66M
154.38M

FY: Financial Year. It represents annual report.

Q: Quarter Report. Q1、Q2、Q3、Q4 represent three-month periodic financial reports.

Check out NLTX latest quarterly and annual financial reports. There are also historical financial reports for you to reference. You can analyze Neoleukin Therapeutics recent business situations by check its income statements, balance sheets, cash flow statements and other tables. This information may help you make smarter investment decisions.